stockportfolio.pro
ANI Pharmaceuticals, Inc. P/E Ratio 2009–2025
ANI Pharmaceuticals, Inc. (ANIP) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +0.6%/yr over 16 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 23.78 | — |
| FY 2024 | — | — |
| FY 2023 | 64.87 | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | 123.34 | +256.2% |
| FY 2018 | 34.63 | — |
| FY 2017 | — | — |
| FY 2016 | 178.29 | +421.5% |
| FY 2015 | 34.19 | +57.0% |
| FY 2014 | 21.77 | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
Source: ANI Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for ANI Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeANI Pharmaceuticals, Inc. — frequently asked questions
What is ANI Pharmaceuticals, Inc.'s price-to-earnings ratio?
ANI Pharmaceuticals, Inc. (ANIP) reported price-to-earnings ratio of 23.78 for fiscal year 2025, per its SEC filings.
How has ANI Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, ANIP's price-to-earnings ratio grew at roughly 0.6% per year (compound annual rate), from 21.77 to 23.78.
Where does this data come from?
Figures are computed from ANI Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.